Teva's New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) TabletsBusiness Wire • 04/16/24
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in ChinaBusiness Wire • 04/11/24
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024Business Wire • 04/09/24
Forget Nvidia: 3 Prominent Billionaire Investors Are Selling It and Buying These 6 Value Stocks InsteadThe Motley Fool • 04/08/24
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024Business Wire • 04/06/24
Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar CandidateBusiness Wire • 04/04/24
Teva UK and Closed Loop Medicine Announce Strategic Partnership to Advance Development of Personalised MedicinesBusiness Wire • 03/26/24
Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in ChinaBusiness Wire • 02/26/24
Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual MeetingBusiness Wire • 02/20/24
Teva Canada Named by Forbes as No. 1 Canadian Employer in Drugs & Biotechnology IndustryBusiness Wire • 02/07/24
MedinCell's Partner Teva Provides Guidance for UZEDY in 2024 and an Update on the Treatment-Candidate of Olanzapine Long-Acting Injectable (LAI)Business Wire • 01/31/24
Teva Pharmaceutical Industries Ltd. (TEVA) Q4 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 01/31/24
Teva Sinks On Lackluster Profit Outlook Despite Walloping Quarterly ProjectionsInvestors Business Daily • 01/31/24